MDGL, WW and AKBA are among pre market gainers
- Gainers: Geron (GERN) +71% wins FDA AdCom backing for blood cancer drug.
- Cardlytics (CDLX) +48% Q4 earnings call release
- Madrigal Pharmaceuticals (MDGL) +25% granted FDA approval for NASH therapy.
- AtlasClear Holdings (ATCH) +16%.
- Akebia Therapeutics (AKBA) +16%.
- RLX Technology (RLX) +9%.
- WW International (WW) +7%.
- Spectral (MDAI) +7%.
- Groupon (GRPN) +6%.
- PowerFleet (PWFL) +6%.
- Acacia Research (ACTG) +6%.
More on pre market gainers & stock
- I Worry That WW International, Formerly Weight Watchers, May Not Survive
- WW International, Inc. (WW) Q4 2023 Earnings Call Transcript
- Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown
- Biggest stock movers today: ADBE, GERN, and more
- WW expects to beat previously given Q1 subscriber guidance
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。